Skip to main content
TOVX logo

TOVX

Theriva Biologics, Inc.
$0.24 +0.00 (+1.21%) At close · Jul 15
Market Cap
$10.48M
Shares
45,892,668

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.24 Open$0.25 Day$0.23–0.25 52W$0.16–0.86 Avg vol 30d12.1M Short int1.5M · 3.2% float · 1.4d Short vol47% Last earningsMay 7, 2025 DataJan 2020–Jul 2026 Filing10-Q · May 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 5, 2026
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Sell Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.7 · calm Equity put/call 0.69
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −8%
below
Price vs 50-day avg −14%
below
RSI (14) 45
neutral
MACD trend Positive
52-week position 12%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −16%
trailing
6-month return +28%
trailing
YTD return +16%
this year
Relative strength +18%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.17% of float · ▼ -51.0% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Squeeze score 40
elevated · 0–100
Fundamentals
Strong
Revenue growth −100%
Y/Y
EPS growth +89%
Y/Y
Free cash flow $-16.7M
Buyback $50.0K
remaining
Balance sheet $11.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 159%
annualized · 1-yr
Max drawdown −79%
past year
ATR 9.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−8% Bearish
Price vs 50-day avg
−14% Bearish
RSI (14)
45 Neutral
MACD trend
Positive Bullish
52-week position
12% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +5 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.17% of float · ▼ -51.0% MoM · 1.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
22 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $0 Now $0 · 12% 52-wk high $1
vs 200-day avg -8% vs 50-day avg -14%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TOVX
Theriva Biologics, Inc.
this stock
$10.48M +15.7% -100.0% 3.2%
ONC
BeOne Medicines Ltd.
$449.85B +2.5% +22179.2% 915.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.36B +5.2% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$71.18B -13.8% +20.8% 16.6 3.3%
ARGX
Argenx SE
$53.68B +2.6% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
22
% held
4.3%
Net QoQ
+669.8K sh
Top holder
GEODE CAPITAL MANAGEMENT,…
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
1.5M
Days to cover
1.4d
Change
-1.5M sh
View
Short Volume
Short vol %
47%
As of
Jul 16, 2026
Short Total
View
Fails to Deliver
FTD shares
23.2K
Value
$6.0K
As of
Jun 30, 2026
View
Off-Exchange
Off-exchange %
67.9%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-23.7M
EPS diluted
$-2.08
View
Buybacks
Remaining
$50.0K
View
Filings
SEC Filings
Latest
8-K
Filed
Jul 7, 2026
This year
17
View
Exempt Offerings
Offering
$13.1M
Filed
Oct 24, 2025
View
Earnings & Events
Earnings Calls
Last call
May 7, 2025
View

Performance

5D 20D 120D MTD YTD
TOVX +1.2% -16.2% +27.8% -2.8% +15.7%
SPY +1.3% -0.2% +10.1% +1.1% +10.7%
vs SPY -0.1% -16.1% +17.7% -3.9% +5.0%

Capital returns

Buyback program · as of Dec 31, 2014
Authorized
Spent (derived)
Remaining
$50,000

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 894158 CUSIP 87164U508 Visit website